A matter of context – time to clinically validate 9-month infant HIV testing in South Africa(?) by Haeri Mazanderani, Ahmad et al.
CORRESPONDENCE
1000       December 2015, Vol. 105, No. 12
A matter of context – time to clinically 
validate 9-month infant HIV testing in 
South Africa(?)
To the Editor: In their recent article, Fairlie et al.[1] rightly point 
out the need for increased identification and early treatment of 
postnatally HIV-infected infants, and suggest that testing at 9 months 
of age using HIV rapid tests (HRTs) will assist in this regard. While 
I agree with them on this point, I am less certain that such a practice 
will reduce the number of HIV polymerase chain reaction (PCR) 
tests done with resultant cost savings, as they have concluded. All 
HRTs that are positive at 9 months will have to be confirmed with 
HIV PCR testing, as maternal antibodies may persist well beyond 
this time point. Delayed seroreversion at >18 months of age in HIV-
uninfected infants has been described in Malawi, Vietnam, Brazil and 
the USA. The US study detected anti-HIV antibodies by enzyme-
linked immunosorbent assay (ELISA) testing in 14% of uninfected 
infants >18 months of age, with the median time to seroreversion 
occurring at >13 months of age.[2] The slower time to seroreversion 
from previously established cut-offs appears to be related to the 
introduction of combination antiretroviral therapy for prevention of 
mother to-child transmission during pregnancy, although the exact 
mechanisms of anti-HIV antibody clearance remain unclear.
Whereas there are anecdotal observations of delayed seroreversion 
in uninfected infants >18 months of age from South Africa (SA), to 
the best of my knowledge there are no local published data regarding 
time to loss of antibodies using rapid tests in infants exposed to 
World Health Organization Option B/B+. Hence there is concern 
that if routine use of HRTs is implemented at 9 months for all HIV-
exposed infants, without clinical validation of HRT kits beforehand, 
a considerable proportion of these infants may require further HIV 
PCR testing. Furthermore, those infants who are still breastfeeding 
will require additional HIV testing 6 weeks after cessation of breast-
feeding, with further repeat HIV PCR testing being required if 
seroreversion still has not occurred at this time. This will not only 
add to the escalating costs of infant diagnosis but will probably have 
a negative impact on the throughput and turnaround time of very 
early infant testing, which should remain the priority, at least for the 
time being. Fairlie et al.[3] base their findings on data suggesting that 
HRTs are able to detect seroreversion in the majority of HIV-exposed 
uninfected infants by 8 - 10 months of age. Whereas this may have 
been the case 10 years ago, it does not necessarily hold true today. 
Before a multicentre nationwide pilot study, as suggested by the 
authors, clinical validation of different HRTs needs to be prioritised 
within the current Option B+ context.
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Fairlie et al. respond: We thank Dr Haeri Mazanderani for his 
interest in our article and for the opportunity to raise the profile of 
the debate on early infant diagnosis (EID) of HIV.
While we acknowledge that the SA Department of Health (DoH) 
guidelines[1] are excellent in terms of establishing EID, there is a gap 
once infants exit the current 18-week visit.[2] If they are breastfeeding 
and test negative before 18 weeks or their mothers previously tested 
HIV negative and seroconvert during breastfeeding, they usually 
do not get tested again until they become ill many years later. 
Despite numerous efforts, measles immunisation rates decrease 
by 18 months; HIV testing rates are low at 18 months, and post-
breastfeeding HIV testing rates are unknown but are assumed to be 
low.[3] Since measles immunisation rates at 9 months are high[3] and 
many infants have discontinued breastfeeding by then, the 9-month 
visit presents a perfect opportunity for an Expanded Programme on 
Immunisation (EPI)-integrated HRT.
We agree that delayed seroreversion in infants would affect the 
model we described by increasing the number of HIV PCR tests 
required at 9 months.[2] Gutierrez et al.[4] ask ‘Has highly active 
antiretroviral therapy increased the time to seroreversion in HIV 
exposed but uninfected children?’ and describe an older median age 
(13.9 months) at seroreversion than previous studies. Their study 
was a retrospective record review of children exposed to maternal 
combination antiretroviral therapy (cART) in the USA.[4] They 
were unable to define a clear mechanism to explain these findings, 
but noted a significant association between late seroreversion and 
protease inhibitor (PI)-based ART (p=0.026) and caesarean section 
(p=0.0052), respectively.[4] The majority of SA pregnant women 
on Option B+ receive first-line cART (a non-nucleoside reverse 
transcriptase inhibitor, usually efavirenz, and not PI-based therapy) 
and SA DoH guidelines do not recommend routine caesarean section 
for HIV-infected women, most of whom give birth vaginally, which 
is associated with earlier seroreversion.[1] In our article we proposed 
using HRTs that have been shown to detect seroreversion at an earlier 
age than the more sensitive laboratory-based HIV ELISA test used 
by Gutierrez et al.[2,4,5] Although unknown, the differences in ART, 
delivery method and proposed rapid test used in SA suggest that our 
HIV-exposed uninfected infants will serorevert at an earlier age.
In the absence of data on the timing of seroreversion in HIV-
exposed infants in the SA context, it is imperative that we do not 
disadvantage children by assuming that the findings of one study 
conducted under different field conditions in a different population 
will apply elsewhere. Even with lower rates of seroreversion at 8 - 10 
months, negative HRTs would be expected to predominate in HIV-
exposed, uninfected infants if appropriate HRTs are used. A test to 
screen children at <1 year on site, at a routine, well-attended EPI 
visit. would provide an additional opportunity to diagnose HIV-
infected children early and initiate ART at a high-risk time, reducing 
morbidity and mortality.
We believe that the time is right to include, rather than exclude, 
children from HIV testing beyond early infant diagnosis. Adults are 
able to test frequently in the health system and are encouraged to do 
so, whereas HIV testing in children errs on the side of fewer tests, yet 
children have the highest morbidity and mortality if not diagnosed early.
Piloting 9-month HRTs at EPI visits in SA for HIV-exposed infants 
will encourage maternal retesting postpartum, as recommended in the 
guidelines, provide an opportunity for infant HIV PCR testing in those 
with a positive HRT, and allow for monitoring of seroreversion rates 
in the context of Option B+ in our local population using a different 
HRT. Furthermore, if maternal HIV antibodies persist in 14% of HIV-
exposed children aged 18 months and seroreversion is incomplete 
at 24 months in HIV-exposed and uninfected children,[4] additional 
HIV PCR testing is urgently required in HRT-positive children aged 
>18 months in SA to prevent lifelong cART in uninfected children.
In summary, while we appreciate the points made, we believe that
the current infant testing strategy lacks an EPI-based test at a fixed
time point after 18 weeks and under 1 year, and that 9-month HIV
testing could enhance EID and earlier ART initiation and replace the
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post-weaning HIV test in HRT-negative infants who are no longer 
breastfeeding. Additional research and monitoring are essential.
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